Cargando…
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine
Oral vaccines, whether living or non-living, viral or bacterial, elicit diminished immune responses or have lower efficacy in developing countries than in developed countries. Here I describe studies with a live oral cholera vaccine that include older children no longer deriving immune support from...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958895/ https://www.ncbi.nlm.nih.gov/pubmed/20920375 http://dx.doi.org/10.1186/1741-7007-8-129 |
_version_ | 1782188391274643456 |
---|---|
author | Levine, Myron M |
author_facet | Levine, Myron M |
author_sort | Levine, Myron M |
collection | PubMed |
description | Oral vaccines, whether living or non-living, viral or bacterial, elicit diminished immune responses or have lower efficacy in developing countries than in developed countries. Here I describe studies with a live oral cholera vaccine that include older children no longer deriving immune support from breast milk or maternal antibodies and that identify some of the factors accounting for the lower immunogenicity, as well as suggesting counter-measures that may enhance the effectiveness of oral immunization in developing countries. The fundamental breakthrough is likely to require reversing effects of the 'environmental enteropathy' that is often present in children living in fecally contaminated, impoverished environments. |
format | Text |
id | pubmed-2958895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29588952010-10-22 Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine Levine, Myron M BMC Biol Opinion Oral vaccines, whether living or non-living, viral or bacterial, elicit diminished immune responses or have lower efficacy in developing countries than in developed countries. Here I describe studies with a live oral cholera vaccine that include older children no longer deriving immune support from breast milk or maternal antibodies and that identify some of the factors accounting for the lower immunogenicity, as well as suggesting counter-measures that may enhance the effectiveness of oral immunization in developing countries. The fundamental breakthrough is likely to require reversing effects of the 'environmental enteropathy' that is often present in children living in fecally contaminated, impoverished environments. BioMed Central 2010-10-04 /pmc/articles/PMC2958895/ /pubmed/20920375 http://dx.doi.org/10.1186/1741-7007-8-129 Text en Copyright ©2010 Levine; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Opinion Levine, Myron M Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title_full | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title_fullStr | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title_full_unstemmed | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title_short | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
title_sort | immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958895/ https://www.ncbi.nlm.nih.gov/pubmed/20920375 http://dx.doi.org/10.1186/1741-7007-8-129 |
work_keys_str_mv | AT levinemyronm immunogenicityandefficacyoforalvaccinesindevelopingcountrieslessonsfromalivecholeravaccine |